Lexicon Pharmaceuticals, Inc. (LXRX)

USD 0.68

(-7.76%)

Market Cap (In USD)

244.8 Million

Revenue (In USD)

1.2 Million

Net Income (In USD)

-177.11 Million

Avg. Volume

2.85 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.62-3.73
PE
-
EPS
-
Beta Value
1.244
ISIN
US5288723027
CUSIP
528872302
CIK
1062822
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Michael Exton Ph.D.
Employee Count
-
Website
https://www.lexpharma.com
Ipo Date
2000-04-07
Details
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.